Share on StockTwits

Ardelyx (NASDAQ:ARDX) released its earnings data on Friday. The company reported $0.44 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.83 by $1.39, Stock Ratings Network.com reports.

Several analysts have recently commented on the stock. Analysts at Wedbush initiated coverage on shares of Ardelyx in a research note on Monday, July 14th. They set an “outperform” rating and a $31.00 price target on the stock. On the ratings front, analysts at Leerink Swann initiated coverage on shares of Ardelyx in a research note on Monday, July 14th. They set an “outperform” rating and a $32.00 price target on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Ardelyx in a research note on Monday, July 14th. They set an “outperform” rating and a $26.00 price target on the stock.

Shares of Ardelyx (NASDAQ:ARDX) opened at 12.03 on Friday. Ardelyx has a 1-year low of $11.37 and a 1-year high of $21.60. The stock’s 50-day moving average is $15.83 and its 200-day moving average is $15.83. The company’s market cap is $215.2 million.

Ardelyx, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of non-systemic, small molecule therapeutics that work in the gastrointestinal (NASDAQ:ARDX), tract to treat cardio-renal, GI and metabolic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.